longevityGraveyard archive2009–2025

Unity Biotechnology

Unity Biotechnology was the flagship public bet on senolytics — the idea that selectively clearing senescent 'zombie' cells could treat the diseases of aging — and its IPO-to-dissolution arc became the field's defining cautionary tale. Founded in 2009 by Nathaniel David with senescence pioneers Judith Campisi and Jan van Deursen, and backed by ARCH Venture Partners, Venrock, Fidelity, Baillie Gifford, the Mayo Clinic and Jeff Bezos, Unity raised more than $300 million all told, including a landmark $116 million Series B in 2016 and roughly $85 million in a May 2018 Nasdaq IPO (ticker UBX). But it never delivered a successful pivotal program. Its first big swing — a senolytic for osteoarthritis of the knee — failed in the clinic in 2020, forcing a painful pivot to ophthalmology.

Years active

2009–2025

Peak valuation

$700M

Total raised

$300M

Peak headcount

150

Founding the senolytics thesis

Unity was built on a genuinely new idea in aging biology. As cells age or take damage they can enter senescence — they stop dividing but refuse to die, lingering in tissue and secreting inflammatory signals that drive age-related disease. Jan van Deursen's mouse work had shown that clearing these cells could delay multiple aging phenotypes, and Judith Campisi had spent a career mapping the senescence-associated secretory phenotype. Founded in 2009 (originally as Forge) by Nathaniel 'Ned' David alongside Campisi, van Deursen and Daohong Zhou, Unity set out to build 'senolytic' medicines that would selectively flush senescent cells from human tissue — a mechanism-first, platform bet on treating aging at its cellular root.

One of the best-funded startups in biotech history

The money followed the story. In October 2016 Unity closed a $116 million Series B — among the largest private financings in biotech at the time — pulling in ARCH, Baillie Gifford, Fidelity, Partner Fund Management, Venrock, WuXi, Mayo Clinic Ventures and, most attention-grabbingly, Jeff Bezos's Bezos Expeditions. A $55 million Series C followed in early 2018, and in May 2018 Unity IPO'd on Nasdaq under UBX, pricing 5 million shares at $17 to raise roughly $85 million and briefly commanding a valuation near a billion dollars. Cumulatively Unity raised more than $300 million — an extraordinary war chest that made it the unambiguous public face of the senolytics movement.

The osteoarthritis miss and the pivot

Unity chose osteoarthritis of the knee as its first proof point, with UBX0101, a locally injected senolytic meant to clear senescent cells from the joint. It was the program the whole thesis was riding on — a large, visible indication where success would validate senolytics as a drug class. In 2020 the Phase 2 study failed: UBX0101 showed no better pain relief than placebo. The setback was existential, wiping out much of the company's value and forcing a wholesale strategic pivot away from its original systemic-disease ambitions toward the eye, where local injection and clear endpoints promised a cleaner shot on goal.

The eye program that couldn't close

Unity re-centered on ophthalmology with UBX1325 (foselutoclax), an intravitreal small-molecule inhibitor of the survival protein Bcl-xL, designed to clear senescent cells from diseased retinal vasculature and offer a longer-acting alternative to the frequent anti-VEGF injections that dominate treatment of diabetic macular edema. Early signals looked encouraging enough to sustain hope. But in the pivotal-scale Phase 2b ASPIRE study, UBX1325 was non-inferior to aflibercept at many timepoints yet missed the primary endpoint at the averaged weeks 20 and 24 — good, but not good enough to build a franchise on. It was the second time in a row that a promising senolytic mechanism had failed to convert into a clean clinical win.

Delisting and dissolution

The end was orderly and total. In May 2025 Unity released the complete 36-week ASPIRE results, closed the trial, and cut essentially its entire remaining workforce while it explored strategic alternatives. With no pipeline and a stock trading like a cash shell, Nasdaq suspended and delisted UBX in July 2025, moving it to the OTC market as UNBX. On September 26, 2025, after stockholders approved a plan of liquidation, Unity filed a certificate of dissolution in Delaware, terminated its leases, and wound down. More than a decade and $300 million-plus in, the most heavily funded, most visible senolytics company ever assembled had produced no approved drug. Unity's real legacy is the lesson it taught the field: that clearing senescent cells is far easier to demonstrate in a mouse than to turn into medicine, and that even a billion-dollar war chest and Nobel-adjacent science guarantee nothing at a Phase 2 endpoint.

What worked, what broke

What worked

Became the marquee public company of the senolytics field, founded by senescence pioneers Judith Campisi and Jan van Deursen and translating their mouse-clearance biology into a human drug program.
Raised more than $300 million across its life, including a landmark $116 million Series B in 2016 backed by ARCH, Baillie Gifford, Fidelity, the Mayo Clinic and Jeff Bezos.
Completed a roughly $85 million Nasdaq IPO in May 2018 (ticker UBX) at a valuation approaching a billion dollars, giving senolytics its most visible listed vehicle.
Advanced multiple novel senolytic candidates — the joint-injected UBX0101 and later the eye drug UBX1325 (foselutoclax) — into controlled mid-stage human trials.
Generated pivotal clinical data that, even in failure, meaningfully informed how the field understands the difficulty of translating senescent-cell clearance into approved therapies.

What broke

Its first lead program, the osteoarthritis senolytic UBX0101, failed its Phase 2 trial in 2020, showing no better pain relief than placebo and destroying the company's original thesis validation.
The replacement lead, the eye drug UBX1325 (foselutoclax), missed the primary endpoint in the Phase 2b ASPIRE study in diabetic macular edema despite non-inferiority to aflibercept at many timepoints.
Two consecutive failures to convert a promising senolytic mechanism into a clean pivotal-scale clinical win left the company with no viable pipeline.
The underlying biology proved far harder to translate than the preclinical mouse data suggested — clearing senescent cells in animals did not reliably produce measurable benefit in humans.
By 2025 the company was a cash-depleted public shell; Nasdaq delisted it, stockholders approved liquidation, and Unity filed for dissolution in Delaware in September 2025.

Sources

Obituary authored Jul 2, 2026 via Sonnet 4.5 + web_search.

What’s new

Join affiliate network